Oncopeptides AB
STO:ONCO

Watchlist Manager
Oncopeptides AB Logo
Oncopeptides AB
STO:ONCO
Watchlist
Price: 4.58 SEK 43.13% Market Closed
Market Cap: 967.6m SEK
Have any thoughts about
Oncopeptides AB?
Write Note

Wall Street
Price Targets

ONCO Price Targets Summary
Oncopeptides AB

Wall Street analysts forecast ONCO stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for ONCO is 5.79 SEK with a low forecast of 1.72 SEK and a high forecast of 14.7 SEK.

Lowest
Price Target
1.72 SEK
63% Downside
Average
Price Target
5.79 SEK
26% Upside
Highest
Price Target
14.7 SEK
221% Upside
Oncopeptides AB Competitors:
Price Targets
NTLA
Intellia Therapeutics Inc
248% Upside
DBV
DBV Technologies SA
108% Upside
688105
Nanjing Vazyme Biotech Co Ltd
7% Upside
PEB
Pacific Edge Ltd
7% Downside
RNA
Avidity Biosciences Inc
117% Upside
CPRX
Catalyst Pharmaceuticals Inc
59% Upside
VITR
Vitrolife AB
50% Upside
300122
Chongqing Zhifei Biological Products Co Ltd
37% Upside

Revenue
Forecast

Revenue Estimate
Oncopeptides AB

The compound annual growth rate of Oncopeptides AB's revenue for the next 2 years is 158%.

N/A
Past Growth
158%
Estimated Growth
Estimates Accuracy
-23%
Average Miss

Operating Income
Forecast

Operating Income Estimate
Oncopeptides AB

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
3%
Average Beat

Net Income
Forecast

Net Income Estimate
Oncopeptides AB

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-50%
Average Miss
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is ONCO's stock price target?
Price Target
5.79 SEK

According to Wall Street analysts, the average 1-year price target for ONCO is 5.79 SEK with a low forecast of 1.72 SEK and a high forecast of 14.7 SEK.

What is Oncopeptides AB's Revenue forecast?
Projected CAGR
158%

The compound annual growth rate of Oncopeptides AB's revenue for the next 2 years is 158%.

Back to Top